GT BIOPHARMA GTB-1550 Multi-Targeted Bispecific Drug Conjugate Strategically Positioned in New Class of ADC Drugs
TAMPA, Florida, June 13, 2019 /PRNewswire/ — GT Biopharma, Inc. (GTBP) (GTBP.PA) an immuno-oncology company developing GTB-1550, a novel multi-target bispecific drug conjugate therapy for the treatment of chemotherapy-refractory B-cell malignancies. Today, Bloomberg discussed antibody-drug conjugates (ADC) as effective cancer therapies having the potential to replace traditional chemotherapy. ADCs are essentially a “trojan horse” therapeutics which have several advantages over traditional chemotherapy including less toxicity and higher efficacy due to a more precise targeting of cancer cells compared to non-cancer cells.
4 Biotech Stocks Taking Center Stage With Cancer-Fighting Treatments
Cancer has been one of the most destructive diseases for more than a century. Even now, a foolproof treatment for the many variants of cancer has not been created. However, that doesn’t mean that a range of companies aren’t spending billions of dollars on cancer research. If a company does come up with a credible cancer drug, it’s likely to be a big focus of the market. Here are several biotech stocks to watch in their quest to become leaders in immunotherapy.
New Security Technology Emerging On The Scene
As long as different countries exist, and opinions vary from person to person, defense and security will be prevalent. Since the technology boom at the turn of the 21stcentury, security technology has advanced at an unprecedented rate.
On-Demand Tech Companies Hit Billion-Dollar Valuations; Here’s How Investors Can Capitalize In The Market
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and GT Biopharma, Midam was hired for a period from 06/07/2019 – 7/07/2019 to publicly disseminate information about GT Biopharma including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of GT Biopharma in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.